WARRENDALE, Pa., November 22, 2011 – MEDRAD, INC., a business of Bayer HealthCare, today unveiled industry-first interoperability with the release of the company’s CertegraTM Informatics Connect.RISTM application. The vendor-neutral informatics application establishes connectivity between MEDRAD’s Stellant® contrast-injection systems, and hospital radiology reporting systems and RIS.
The Connect.RISTM application auto-populates contrast-injection records into radiology reporting systems and RIS – eliminating the need for radiologists to look-up or dictate contrast-injection records. In addition, the application delivers consistent patient records throughout facilities, and supports accurate and efficient billing and reconciliation processes.
“MEDRAD is leveraging market-leading interoperability that eliminates the need for radiologists to look-up and dictate contrast injection records,“ said Anthony Cinalli, Vice President, Radiology Marketing and Sales, MEDRAD, INC. “Our informatics solutions speed-up the information flow and enable actionable data to lend clinical and administrative insight to radiology professionals throughout the facility.”
Additional Certegra software and applications include:
Manage.Report™ Application (data-driven reporting and analysis across CT suites and shifts):
- Continually measures and helps radiology professionals actively manage performance department-wide
- Helps to identify and uncover root-cause of atypical events, re-scans and more
Connect.PACSTM application (PACS integration):
- Automatically captures and integrates CT contrast-injection records (including the protocols programmed and delivered) into PACS
- Provides radiologists new information concerning the contrast-injections associated with clinical images as they read
- Allows radiologists to relate their evaluation of clinical images to any changes made at the point-of-care to the protocol prescribed
P3T® software line (personalized CT contrast protocols for abdomen, cardiac and Pulmonary Angiography studies):
- Enables consistent protocol optimization across patient populations and simplifies complex study administration
- Enables a higher percentage of diagnostic studies*(2)(3)(4) – and reduces the potential for unnecessary rescans4
About MEDRAD, INC.
MEDRAD develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. MEDRAD is a two-time recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence (2003 and 2010). The company’s world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer HealthCare. More company information is available at www.medrad.com.
Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.9 billion (2010), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
1DF-119378 rev 01
*At a slightly higher contrast dose when compared to a standard protocol of 80ml
2Yanaga, Y. et al. Pancreas: Patient Body Weight-tailored Contrast Material Injection Protocol versus Fixed Dose Protocol at Dynamic CT. Radiology 2007;245: 475-487
3Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible, MD, PhD. Study supported by MEDRAD
4510(k) FDA clearance number: K082905